AbbVie shares decline for a seventh straight session, underperforming the S&P 500 as losses deepen over the past week.
AbbVie (ABBV) dropped 1.30% to $244.78 in Tuesday afternoon trading, marking its seventh consecutive session of declines. The stock has fallen 5.1% over the past six trading sessions, sharply contrasting with the S&P 500’s 0.44% gain in the same period.
The extended slide follows a broader trend of underperformance, though year-to-date figures were not fully detailed. The S&P 500’s modest advance highlights AbbVie’s relative weakness amid recent market conditions.
No immediate market reaction was specified, but the persistent downturn reflects investor sentiment toward the stock.